Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 clinical study of ANB-504

Next Previous
X
Search
Trial Profile

Phase 1 clinical study of ANB-504

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANB-504 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions

    • Most Recent Events

    • 22 Oct 2021 New trial record
    • 30 Sep 2021 According to an AnaBios Corporation media release, the company received a $1,734,409 SBIR grant from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health which will support the execution of Investigational New Drug-enabling studies aimed at obtaining Food and Drug Administration approval for this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top